

RABISIN

Boehringer
Ingelheim



923067

Suspension for injection

Dogs, Cats, Horses, Sheep, Cattle, Ferrets

Qualitative and quantitative composition

- Rabies virus glycoproteins ≥ 1 IU
- Aluminium (as hydroxide) 1.7 mg
- Excipient, qs 1 dose of 1 ml

Indications

Vaccination of dogs, cats, horses, sheep, cattle and ferrets against rabies.

Administration and dosage

Inject by subcutaneous or intramuscular route a 1-ml dose according to the following schedule:

Species	Primary vaccination		Boosters
Dogs, cats	1 injection from 12 weeks* of age		1 year after primary vaccination Then at intervals of up to 3 years**
Ferrets	1 injection from 3 months of age		Annual
Horses	Aged less than 6 months	1 injection from 4 months of age*** followed by a 2nd injection 1 month after	Annual
	From 6 months of age	1 injection	
Cattle, Sheep	Aged less than 9 months	1 injection from 4 months of age*** followed by a 2nd injection between 9 and 12 months of age	Annual
	From 9 months of age	1 injection	

* In case a dog or a cat was vaccinated before 12 w. of age, the primary vaccination scheme should be completed by an injection given at 12w. of age or older.

** In any case, the revaccination period should comply with legislation in force in the country.

*** In case a horse, a cattle or a sheep was vaccinated before 4m. of age, the primary vaccination scheme should be completed by an injection given at 4m. of age or older.

Contra-indications

Do not inject the vaccine subcutaneously in horses.

Special precautions for use

Vaccinate only perfectly healthy animals, correctly wormed at least 10 days before vaccination.

Undesirable effects

- As with any vaccine, a hypersensitivity reaction may occur. These are rare and appropriate symptomatic treatment should be administered.
- The presence of aluminium hydroxide may sometimes induce the formation of a small and transient nodule at the injection site.

Overdose (symptoms, emergency procedures, antidotes)

No undesirable effects have been observed after the administration of several doses of vaccine.

Immunological properties

Inactivated vaccine in adjuvant against rabies. After administration, the vaccine induces an immune status against rabies demonstrated by challenge and by the presence of antibodies.

Use during pregnancy and lactation

No adverse effects have been recorded in female animals during pregnancy.

Interactions: Unknown.

Incompatibilities: Unknown.

Special precautions for the disposal of unused products or waste materials derived from such products

The vaccine being inactivated, no special precaution must be taken with unused product.

Any unused product or waste materials derived from such products should be disposed of in accordance with the local requirements.

Storage

Store at 2°C - 8°C (in a refrigerator), protected from light.

For veterinary use only

PACK OPS LYON GRAPHIC ARTWORK APPROVAL

Code: 0 053 923067	VERSION PTG : 0072 Version : B 040516	COLORS Noir/Black
PRODUCT: RABISIN NOT RECTO	INITIALS: Nse - PICTURAL AN	Please use the official PANTONE® (P) matching system for an accurate color representation.
COUNTRY: STD ASIE (ELF)	VERSION - DATE: A 16/12/19 - 15h45	
Dimensions à plat (mm): 70x330 Dimensions plié(e)s: 70x30		
PRINTED BASIS CODE (if applicable): NA	CANCEL AND REPLACE: NA	

Marketing approval:

COMPLETE
NAME:
DATE +
SIGNATURE:

Regulatory approval:

COMPLETE
NAME:
DATE +
SIGNATURE:

NOT PRINTABLE
NON IMPRIMABLE

TECHNICAL NOTE(S) - INFO(S) TECHNIQUE

- Artwork identification(s)
- Text areas / zones de textes
- Dieline / Découpe